Loading
NYSEHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
$9.32
+$0.065 · +0.70%
Haleon plc is a significant global entity in the consumer healthcare sector, engaging in the entire process from scientific research and development to the production and worldwide distribution of various wellness goods. The company's reach extends across North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific region. Its diverse product portfolio encompasses therapeutic solutions for oral care, pain management, respiratory well-being, and digestive health, alongside a comprehensive range of vitamins, minerals, and other dietary supplements. Noteworthy brands within its collection include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. Established in 2021, the company was initially known as DRVW 2022 plc before officially changing its name to Haleon plc in February 2022. It is headquartered in Brentford, United Kingdom.
Latest quote
$9.32
+$0.065 · +0.70%
After-hours
$9.33
+$0.01 · +0.11%
Oct 9, 6:03 PM ET
Regular session · ET · Market data may be delayed.
Haleon plc is a significant global entity in the consumer healthcare sector, engaging in the entire process from scientific research and development to the production and worldwide distribution of various wellness goods. The company's reach extends across North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific region. Its diverse product portfolio encompasses therapeutic solutions for oral care, pain management, respiratory well-being, and digestive health, alongside a comprehensive range of vitamins, minerals, and other dietary supplements. Noteworthy brands within its collection include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. Established in 2021, the company was initially known as DRVW 2022 plc before officially changing its name to Haleon plc in February 2022. It is headquartered in Brentford, United Kingdom.
Day range
Current $9.32
52-week range
Current $9.32
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
88
Deep Value
Sentiment
52
Mixed
Risk
22
Moderate Risk
Momentum
42
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Haleon plc is a significant global entity in the consumer healthcare sector, engaging in the entire process from scientific research and development to the production and worldwide distribution of various wellness goods. The company's reach extends across North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific region. Its diverse product portfolio encompasses therapeutic solutions for oral care, pain management, respiratory well-being, and digestive health, alongside a comprehensive range of vitamins, minerals, and other dietary supplements. Noteworthy brands within its collection include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. Established in 2021, the company was initially known as DRVW 2022 plc before officially changing its name to Haleon plc in February 2022. It is headquartered in Brentford, United Kingdom.
Day range
Current $9.32
52-week range
Current $9.32
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (GBP) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 11.03B GBP | 11.23B GBP | 11.3B GBP | 10.86B GBP | 9.55B GBP |
| Cost of goods sold | 3.83B GBP | 4.29B GBP | 4.34B GBP | 4.28B GBP | 3.6B GBP |
| Gross profit | 6.99B GBP | 6.95B GBP | 6.96B GBP | 6.58B GBP | 5.95B GBP |
| Research and development | 308.1M GBP | 298M GBP | 311M GBP | 300M GBP | 257M GBP |
| Selling, general, and administrative | 4.36B GBP | 4.33B GBP | 4.29B GBP | 4.04B GBP | 3.79B GBP |
| Operating expenses | 4.43B GBP | 4.74B GBP | 4.97B GBP | 4.75B GBP | 4.31B GBP |
| Interest income | 76.29M GBP | 55M GBP | 14M GBP | 68.98M GBP | 13M GBP |
| Interest expense | 332.55M GBP | 394M GBP | 414M GBP | 347.36M GBP | 16M GBP |
| Depreciation and amortization | 352.11M GBP | 324M GBP | 309M GBP | 287M GBP | 268M GBP |
| Operating income | 2.41B GBP | 2.21B GBP | 2B GBP | 1.83B GBP | 1.64B GBP |
| Net income | 1.63B GBP | 1.44B GBP | 1.05B GBP | 1.06B GBP | 1.39B GBP |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$10.20
9.44% upsideLimited analyst sample: 4 ratings. Interpret the distribution with caution.
Funds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR Portfolio Developed World ex-US ETFSPDW51.09M0.13%40.77B USD0.03%$49.98+0.64%
VanEck Pharmaceutical ETFPPH39M3.80%1.03B USD0.36%$110.49+1.20%
Principal Exchange-Traded Funds - Principal International Equity ETFPIEQ32.95M2.49%1.3B USD0.48%$35.59+0.57%
Avantis International Equity ETFAVDE8.54M0.04%19.06B USD0.23%$89.80+0.58%
Portfolio Building Block World Pharma and Biotech Index ETFPBPH5.61M0.54%1.04B USD0.13%$28.3551+1.40%
Scharf Global Opportunity ETFGKAT4.36M2.65%163.9M USD0.59%$44.7957+0.66%
ETF Opportunities Trust - AQE Core ETFAQEC4.22M0.70%605.65M USD0.49%$26.02+0.35%
Franklin ClearBridge Enhanced Income ETFYLDE3.95M2.27%171.68M USD0.48%$55.525+0.31%State Street SPDR Portfolio Developed World ex-US ETFSPDWVanEck Pharmaceutical ETFPPHPrincipal Exchange-Traded Funds - Principal International Equity ETFPIEQAvantis International Equity ETFAVDEPortfolio Building Block World Pharma and Biotech Index ETFPBPHScharf Global Opportunity ETFGKATETF Opportunities Trust - AQE Core ETFAQECFranklin ClearBridge Enhanced Income ETFYLDEAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
